MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
LivaNova PLC Operating Income 2011-2026 | LIVN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income LivaNova PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 199 M | 129 M | -68.5 M | -76.8 M | -784 K | -274 M | -172 M | -248 M | 96.5 M | 33.4 M | 88.7 M | 80 M | 78.3 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | -274 M | -10.3 M |
Quarterly Operating Income LivaNova PLC
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54 M | 54.2 M | 48.6 M | - | 35.6 M | 40.2 M | 16.2 M | - | 4.46 M | 17.4 M | -2.34 M | - | -132 M | 31.8 M | 9.5 M | 24.8 M | 16.4 M | -36.3 M | -5.7 M | -249 M | -7.55 M | -16.7 M | -15.2 M | -144 M | 25.8 M | -29.9 M | -20.8 M | -276 M | -5.76 M | 21.6 M | 12.5 M | 18.9 M | 30 M | 27.8 M | 19.7 M | -14.9 M | 30.4 M | 25 M | -9.07 M | - | -26.4 M | -26.4 M | 16.7 M | - | 26.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.2 M | -276 M | -10.3 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 13.11 | - | $ 1.77 B |  USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 10.66 | 2.7 % | $ 382 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 25.93 | 0.27 % | $ 219 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.48 | 4.77 % | $ 130 M |  France |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.13 | 4.41 % | $ 1.29 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 11.2 | 0.18 % | $ 317 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 56.2 | 0.15 % | $ 1.65 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.63 | 2.46 % | $ 39.2 M | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.04 | 0.97 % | $ 17.6 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.15 | 0.6 % | $ 355 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 5.01 | 4.71 % | $ 1.06 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 91.66 | 1.61 % | $ 12.4 B | USA |
 |
NanoVibronix
NAOV
|
-22.9 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.75 | 0.11 % | $ 1.14 B | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.33 | 12.02 % | $ 6.46 M | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 85.96 | -2.92 % | $ 2.99 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 84.2 | 0.81 % | $ 49.2 B | USA |
 |
Stryker Corporation
SYK
|
4.89 B | $ 302.2 | -4.08 % | $ 116 B | USA |
 |
TransMedics Group
TMDX
|
109 M | $ 99.62 | -1.16 % | $ 3.39 B | USA |
 |
Tandem Diabetes Care
TNDM
|
8.29 M | $ 19.85 | 1.66 % | $ 1.35 B | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.45 | 4.11 % | $ 65.2 M | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.37 | 6.64 % | $ 55.7 M | USA |
 |
MiMedx Group
MDXG
|
63.9 M | $ 3.62 | 7.59 % | $ 535 M | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.89 | 3.01 % | $ 37.3 M | USA |